This review systematically examines the structural architecture, developmental evolution, and mechanistic foundations of ADCs, with a focused evaluation of clinical evidence supporting ADCs targeting HER2, TROP2, c-MET, HER3, CEACAM5, and B7-H3 in advanced NSCLC. This evidence concerns the gene CEACAM5 and non-small cell lung carcinoma.